Key Takeaways

  • The United States is "massively losing" to China in biotech clinical trials because China has built an "industrialized clinical trial infrastructure" that is faster and cheaper.
  • A single first-in-human Investigational New Drug (IND) application in the US can cost $25 million and take 18 months to compile, as was the case for Strand Therapeutics' 22,000-page document.
  • Jake Becraft advocates for significant FDA reform, specifically removing the agency's direct permission-based oversight for early-stage trials.
  • The proposed solution is a Proposed US Clinical Trial Notification (CTN) System, similar to Australia's, which empowers hospital IRBs for faster, more decentralized drug testing.
  • Becraft views this regulatory shift as "existential" for US biotech, giving it a "50% likelihood" of being enacted within the next two years.

The Proposed US Clinical Trial Notification (CTN) System

Jake Becraft argues that America's biotech advantage is eroding because of slow, costly regulatory hurdles. His solution isn't theoretical; it's a proven model already in use elsewhere. He proposes adopting a Proposed US Clinical Trial Notification (CTN) System:

  • Step 1: Notify Regulators: You notify the regulators, 'hey, we're going to run a trial.' It's not a pass system. There are exceptions. Certain types of drugs still need to go through them for like formal approval, but for the most part, you can notify them.
  • Step 2: Hospital IRB Approval: Go to the IRB, the IRB can say, 'Yep, we think this is safe enough.' The IRB is going to assess that and make a call... you distribute this workload across the IRBs that exist throughout the United States. And they get certified with the FDA to be able to approve this.
  • Goal: Streamline and Accelerate: This system allows for more rapid and cost-effective testing of new drugs, decentralizes the safety review process, and expands access to trials for American patients beyond major medical centers.

When This Works (and When It Doesn't)

Becraft highlights that this CTN system is already operational in countries like Australia and China, allowing for quicker and cheaper first-in-human trials while maintaining patient safety. The core idea is that hospitals and their Institutional Review Boards (IRBs) are highly incentivized to prevent patient harm, given their reputations and liability. This decentralizes the initial safety review, speeding up early-stage drug development, especially for therapies where preclinical data provides a clear safety profile. It also democratizes access to clinical trials, moving them beyond just a few major academic centers.

However, this approach isn't a silver bullet. It might face challenges with entirely new therapeutic modalities, like advanced gene-editing technologies, where the risks are truly unknown and IRB expertise might be limited compared to specialized FDA panels. There's also the question of consistency: ensuring thousands of IRBs maintain rigorous, standardized safety reviews would require robust FDA certification and auditing. A CTN system relies heavily on trust in the IRBs' independence and competence, and any perception of a race to the bottom could undermine public and political support. It's best suited for incremental innovations or therapies with well-understood mechanisms where the primary goal is efficient human safety validation.

What to Do With This

If you're a biotech founder facing the daunting prospect of a traditional Investigational New Drug (IND) application, don't just accept the status quo. Start by identifying the specific regulatory hurdles for your next preclinical milestone. Then, instead of solely planning for the existing IND path, map out how your proposed first-in-human trial would look under Becraft's CTN system.

Step 1: Notify Regulators: Imagine writing a concise notification to the FDA for your lead candidate (e.g., an mRNA vaccine for a rare infectious disease). What critical safety data and preclinical findings would you prioritize to quickly satisfy a notification requirement, rather than compiling a 22,000-page permission application?

Step 2: Hospital IRB Approval: Research 2-3 hospital IRBs known for early-phase trials in your therapeutic area. Draft a mock protocol outline that specifically addresses their safety concerns for your innovative treatment. This exercise will help you distinguish between genuine patient safety questions and the bureaucratic overhead of the current system, giving you a clearer path forward if the CTN system becomes a reality.